The overall prevalence of MAGE-A4 gene expression was the same as observed in our study (35%); MAGE-A4 positivity was particularly prevalent (≥20% of samples) in esophageal cancers (55%), head and neck cancers (38%), gastric cancers (35%), and ovarian cancers (34%). This evidence concerns the gene MAGEA4 and gastric cancer.